COVID-19

[Clinical infectious Diseases] COVID-19 patients infected with the delta variant exhibited prolonged viable viral shedding with more severe symptoms than those infected with non-delta variants.

[Nature] Researchers in a pivotal African clinical trial have been denied access to a key COVID-19 antiviral drug, frustrating efforts to test the treatment in African populations and in combination with therapies that could potentially expand its utility on the continent.

[iScience] The authors hypothesized that viral mimic-priming improved mesnchymal stem cells' abilities to rebalance the dysregulated immune responses in COVID-19.

[STAT News] 15 months ago, Congress showered the agency with a massive $1.2 billion to research the mysterious cases of patients who never fully recover from COVID-19 infections. But so far the NIH has brought in just 3% of the patients it plans to recruit.

[Nature Communications] Scientists showed that neuroinflammation, microhemorrhages, brain hypoxia, and neuropathology that is consistent with hypoxic-ischemic injury in SARS-CoV-2 infected non-human primates, including evidence of neuron degeneration and apoptosis.

[Proceedings of the National Academy of Sciences of the United States of America] To investigate viral spread, primary human airway epithelial cell cultures were infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and host–virus interactions were examined via electron microscopy, immunohistochemistry, RNA in situ hybridization, and gene expression analyses.